Women usher in strength training's new era
Gyms are making space.
The future of strength training is female.
New flex. Once dominated by men, Crunch Fitness CEO Jim Rowley told Bloomberg that women now account for 50%+ of lifting platform usage.
Meanwhile, Planet Fitness is removing more than 40% of cardio machines across 1,700 locations to meet growing demand for weights and functional training, Fitt Insider reports.
Validated. Between 2011 and 2021, women's use of free weights increased by 150%, while resistance machine use jumped 558%, per Harrison Co. On Strava, strength training uploads climbed 25% in 2024, making it the fastest-growing sport among women.
Longevity lift. More than aesthetics, resistance training is essential for aging well, boosting bone density, preserving muscle, and improving metabolic health. A call to arms, experts like Dr. Stacy Sims and Dr. Gabrielle Lyon are pushing strength as a cornerstone of women's healthspan.
Stronger together. Still, 73% of US women—and 83% of women 65+—don't meet CDC strength guidelines, creating a major opportunity for services, coaching, and products tailored to female lifters.
Punchline: Strength is the new cardio, and women are leading the charge — transforming gyms, supplements, and the future of healthy aging.
This story was produced by Fitt Insider and reviewed and distributed by Stacker.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Incyte replaces CEO Hoppenot with dealmaker Meury
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis for nearly $1 billion, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Prior to those posts, Meury was chief commercial officer at Allergan. Hoppenot will remain on Incyte's board of directors through the end of this year to aid Meury's transition into the CEO role. Alongside the succession, Julian Baker, managing partner of biotechnology investor Baker Bros. Advisors and lead independent director for Incyte, was elected board chair. Much of Hoppenot's time at Incyte focused on what he once described as 'single asset syndrome.' The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. Last year, Jakafi brought in nearly $2.8 billion in sales. But Jakafi's main patents expire in 2028, a date that for years now has been on investors' radar as they've pressed Incyte on what it expects will take the drug's place. Early in Hoppenot's tenure, the answer looked like a cancer medicine called epacadostat, which Incyte believed could become a cornerstone of immunotherapy combinations. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio. The company now owns six other approved drugs, including a cream formulation of Jakafi's main ingredient that's proved useful treating atopic dermatitis and vitiligo. 'Hervé joined Incyte in 2014 when it was a single product, U.S.-only company,' said board member Baker, in a statement. 'During Hervé's tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today.' However, Incyte's other drugs don't make it much money. Jakafi and the cream formulation of the drug Incyte sells as Opzelura accounted for 91% of net product revenues last year. (The company also earned nearly $600 million in royalty revenues.) Stephen Willey, an analyst at Stifel, gives Hoppenot credit for increasing Incyte revenues by more than 10 times during his time as CEO. But, in a Thursday note to clients, he added that some investors grew frustrated with the company's high research and development spending without a clear post-Jakafi plan. Shaping those plans will now fall to Meury, who gained industry visibility by guiding his prior two companies to lucrative acquisitions. 'We expect the immediate reaction from investors will be an expectation that [Incyte] could now become an M&A target, simply because Mr. Meury sold Anthos ... and sold [Karuna],' wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. Shares in Incyte, which have fallen by 30% over the past five years, rose by more than 4% in Thursday morning trading on the CEO news. 'It has been a privilege to lead Incyte over the past eleven years,' Hoppenot said in the company's statement. 'I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever.' Incyte expects multiple pivotal trial readouts this year, along with proof-of-concept data for several pipeline candidates. Recommended Reading Unblinded: Hervé Hoppenot on solving Incyte's 'single asset syndrome' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
38 minutes ago
- CBS News
After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture
New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes A new medical technology that acts like a seatbelt is aimed at reducing the risk of repeated knee injuries often suffered by athletes of all levels. Seventeen-year-old Nicholas Pohorilenko is ready to start practice after tearing his ACL almost two years ago. "Honestly, I thought my like sports career was over because a lot of people don't come back from that," Pohorilenko said. The tight end for Council Rock South High School said it happened when another player's helmet crashed into his knee. "I was able to jog off the field, and then I got to the sidelines and I like literally couldn't walk," he said, "It was horrible." The ACL –anterior cruciate ligament – is a vital structure in the knee. A tear or rupture requires surgery and a long rehab. "Our young athletes who, in general, have the highest rate of ACL injury also, unfortunately, come with the highest rates of re-rupture," said Dr. Sommer Hammoud with Rothman Orthopaedics. Dr. Hammoud is using new technology to reduce the risk of a potential re-rupture. She said it's like a seatbelt that's surgically implanted with the graft, which is used to repair the ACL. It prevents the graft from being overstretched, acting like an internal brace. Arthrex "I think this is the simplest thing that one can add to a ligament repair or reconstruction that is likely gonna have a huge potential benefit to the patient," said Dr. Hammoud. Pohorilenko said the rehab was long and difficult, but he's happy he has the so-called seatbelt in his repaired knee. "I think it's great, like, cause you people tear their ACLs multiple, multiple times," he said. "With this, tear it once, you get this technology and you're done." Best of all, his knee is fine and he'll be back playing the game he loves for his senior season. Since the technology is relatively new, doctors don't know yet exactly how much it will reduce re-ruptures of the ACL. CBS Philadelphia
Washington Post
40 minutes ago
- Washington Post
Angels manager Ron Washington to miss rest of season with unspecified medical issue
ANAHEIM, Calif. — Los Angeles Angels manager Ron Washington will miss the rest of the season because of an unspecified medical issue, the team said Friday. Washington, the oldest manager in the major leagues at 73, has been sidelined for the past week. He experienced shortness of breath and appeared fatigued toward the end of a four-game series at the New York Yankees that ended on June 19. He flew back to Southern California, underwent a series of tests and was placed on medical leave.
